SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

EYE Nova Eye Medical Limited

Healthcare · Medical Devices · website
$0.13
52wk 0.10 – 0.20
Overall
62.8
Value
73.4
Growth
100.0
Health
80.1
Quality
0.0
Momentum
38.7
Dividend
—
Price
About Nova Eye Medical Limited

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. The company operates through Glaucoma Surgical Devices and AlphaRET segments. It offers 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Price analytics

Returns

1 day -1.9%
1 week -3.7%
1 month -3.7%
3 months 18.2%
6 months 4.0%
1 year -16.1%
3 years -42.2%

Risk

Volatility (1y ann.) 68.9%
Beta vs ASX 200 0.57
Sharpe (1y) 0.03
VaR 95% (1-day) -6.2%
Max drawdown (1y) -48.7%
Off 1-year high -33.3%

Technicals

RSI(14) 45
vs 50DMA -5.7%
vs 200DMA -4.3%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 73.4
Trailing P/E
—
Forward P/E
69
PEG ratio
26
EV / EBITDA
100
Price / Book
75
Price / Sales
97
Growth 100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 80.1
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
55
Debt / Equity
100
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 38.7
6-month return vs ASX 200
59
Price vs 200-day average
36
Price vs 50-day average
22
Position in 52-week range
29

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$37.04M
P/E (trailing)
—
P/E (forward)
16.25
EPS (trailing)
-0.02
Dividend yield
—
Payout ratio
0.0%
Beta
0.94
EV / EBITDA
-11.27
Price / Book
2.60
ROE
-26.1%
Operating margin
-5.0%
Net margin
-12.4%
Total cash
$964,000
Total debt
$2.39M
Current ratio
1.74
Debt / Equity
0.17
Free cash flow
$-1.95M
Avg volume
214,248
Latest annual results (FY ending 30 Jun 2026)
  • Revenue—
  • Gross profit—
  • Operating income—
  • Net income—
  • Diluted EPS-0.02
  • Free cash flow—
  • Net debt—
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4